Altimmune

ALT

Market cap $320M

Overview Fund Activity

3.63 USD

+0.04

1.11%

At close Updated Sep 16, 10:58 AM EDT

1 day

1.11%

5 days

-3.97%

1 month

1.97%

3 months

-47.16%

6 months

-39.2%

Year to date

-48.95%

1 year

-52.11%

5 years

-73.77%

10 years

-99.17%

About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 59

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

82% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 39

26% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 31

16% more call options, than puts

Call options by funds: $26.2M | Put options by funds: $22.6M

3% more funds holding

Funds holding: 173 [Q1] → 179 (+6) [Q2]

3.32% less ownership

Funds ownership: 49.53% [Q1] → 46.21% (-3.32%) [Q2]

24% less capital invested

Capital invested by funds: $191M [Q1] → $145M (-$45.9M) [Q2]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

231% upside

Avg. target

$17.25

375% upside

High target

$24

561% upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	$12	Buy Reiterated	13 Aug 2025
UBS Eliana Merle	$24	Buy Maintained	13 Aug 2025
B. Riley Securities Mayank Mamtani	$18	Buy Maintained	13 Aug 2025
JMP Securities Jonathan Wolleben	$15	Market Outperform Maintained	10 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 74 articles about ALT published over the past 30 days

Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

NEW YORK , Sept. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.

Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT

NEW YORK , Sept. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M.

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Altimmune, Inc. (NASDAQ:ALT) and SelectQuote, Inc. (NYSE:SLQT). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

NEW YORK, Sept. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT

Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel

SAN DIEGO, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, announces that a class action lawsuit has been filed on behalf of investors who purchased securities of Altimmune, Inc. (“Altimmune”) (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025.

Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel

See News Rankings

Charts implemented using Lightweight Charts™